Story

Morgan Stanley Q2 Profit Jumps on Investment Banking Surge

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Morgan Stanley Q2 Profit Jumps on Investment Banking Surge

Summary

The investment bank reported a significant rise in second-quarter profit, with net income soaring as a record-breaking environment for mergers and acquisitions boosted advisory fees.

Text size
Background

Morgan Stanley (MS) on Wednesday reported a substantial increase in second-quarter profit, driven by a surge in its investment banking division amid a booming market for corporate dealmaking and initial public offerings.

The bank's performance reflects an industry-wide windfall from heightened M&A activity, fueled by strong equity markets and a favorable regulatory environment, according to a report from Reuters.

Dealmaking Drives Results

Morgan Stanley's financial results for the three months ending June 30 showed significant year-over-year growth. The bank's investment banking revenue was a key driver, climbing to $2.44 billion from $1.54 billion in the same period a year earlier.

Key financial highlights from the report include:

Sample IUX Markets – In-articleAd
  • Net Income: Rose to $5.58 billion, compared with $3.54 billion a year prior.
  • Earnings Per Share (EPS): Increased to $3.46 per share, up from $2.13 per share in the second quarter of the previous year.

A Record M&A Environment

The bank's strong quarter was underpinned by a historic period for global M&A. The total value of announced deals reached $2.8 trillion in the first half of the year, a 48% increase from the prior year and the highest first-half total since LSEG records began in 1980.

Morgan Stanley played a central role in several major transactions during the quarter. It served as a financial advisor on Fertitta Entertainment’s $17.6 billion agreement to acquire Caesars Entertainment and was a lead underwriter for the landmark market debut of Elon Musk’s SpaceX. The firm's results mirror similar jumps in investment banking revenue reported by competitors like JPMorgan Chase, Bank of America, and Goldman Sachs.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST